US 10,767,167 B2Granted

Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes

AssigneesInstitut Pasteur, Inserm (Institut National De La Sante Et De La Recherche Medicale)

InventorsPierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut

Life of this patent

Estimating the term…

Loading patent…

Abstract

This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.

Claims20

Dependent claims

A method of inducing an HLA-A2 and/or HLA-B7-restricted immune response against at least one hTERT epitope, comprising:

A) administering to an animal a vector comprising a polynucleotide sequence that encodes a modified hTERT protein comprising the amino acid sequence of SEQ ID NO:
39;
B) expressing the modified hTERT protein;
and
C) inducing:
1) an HLA-A2-restricted immune response against at least one hTERT epitope selected from:
a) p540, and
b) pY572;
and/or
2) inducing an HLA-B7-restricted immune response against at least one hTERT epitope selected from:
a)
(SEQ ID NO:
6)
MPRAPRCRA (p1),
b)
(SEQ ID NO:
7)
APRCRAVRSL (p4),
c)
(SEQ ID NO:
8)
APSFRQVSCL (p68),
d)
(SEQ ID NO:
9)
RPAEEATSL (p277),
e)
(SEQ ID NO:
10)
RPSFLLSSL (p342),
and
f)
(SEQ ID NO:
11)
RPSLTGARRL (p351).

32 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/481,452Filed 6 Apr 2017 · continuation in part
Priority: EP 0529162729 Jul 2005
Published: US 2017/0298328 A119 Oct 2017
Granted: 8 Sep 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

C12N 9/1276
Nucleotidyltransferases: rNA-directed DNA polymerase , i.e. reverse transcriptase or telomerase
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/4246
Enzymes: telomerase or [telomerase reverse transcriptase [TERT]
C12N 9/1241
Transferring phosphorus containing groups, e.g. kinases: nucleotidyltransferases

Family

PCT/EP2006/007571Parent of this continuation · filed 31 Jul 2006
Application13/975,404Parent of this continuation-in-part · filed 26 Aug 2013
US 8,858,931 B2Parent of this continuation · filed 14 Oct 2014
US 2017/0298328 A1Pre-grant publication · published 19 Oct 2017
US 9,624,479 B2Parent of this continuation-in-part
Application11/795,027Parent of this continuation
Application13/975,404Parent of this continuation
US 2010/0172878 A1Published application
US 2014/0056932 A1Published application
US 10,767,167 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key